BE2011C027I2 - - Google Patents

Download PDF

Info

Publication number
BE2011C027I2
BE2011C027I2 BE2011C027C BE2011C027C BE2011C027I2 BE 2011C027 I2 BE2011C027 I2 BE 2011C027I2 BE 2011C027 C BE2011C027 C BE 2011C027C BE 2011C027 C BE2011C027 C BE 2011C027C BE 2011C027 I2 BE2011C027 I2 BE 2011C027I2
Authority
BE
Belgium
Prior art keywords
aqueous liquid
liquid preparation
rhinitis
preservative
useful
Prior art date
Application number
BE2011C027C
Other languages
French (fr)
Original Assignee
Senju Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32767329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2011C027(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Senju Pharma Co filed Critical Senju Pharma Co
Publication of BE2011C027I2 publication Critical patent/BE2011C027I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).
BE2011C027C 2003-01-21 2011-08-30 BE2011C027I2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003012427 2003-01-21

Publications (1)

Publication Number Publication Date
BE2011C027I2 true BE2011C027I2 (en) 2023-03-07

Family

ID=32767329

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2011C027C BE2011C027I2 (en) 2003-01-21 2011-08-30

Country Status (15)

Country Link
US (9) US8129431B2 (en)
EP (1) EP1586316B1 (en)
JP (1) JP4500261B2 (en)
KR (1) KR101059711B1 (en)
CN (1) CN100341498C (en)
AT (1) ATE393627T1 (en)
BE (1) BE2011C027I2 (en)
CA (2) CA3043910A1 (en)
DE (2) DE602004013420T2 (en)
ES (1) ES2301964T3 (en)
FR (1) FR11C0031I2 (en)
HU (1) HUS1100022I1 (en)
MX (1) MX2016014404A (en)
PT (1) PT1586316E (en)
WO (2) WO2004064828A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6552020B1 (en) * 1999-07-30 2003-04-22 Allergan, Inc. Compositions including antibiotics and methods for using same
ATE393627T1 (en) 2003-01-21 2008-05-15 Senju Pharma Co AQUEOUS LIQUID PREPARATION WITH 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID
MX2007001172A (en) * 2004-11-05 2007-03-12 Senju Pharma Co Aqueous eye drops with accelerated intraocular migration.
TWI358290B (en) * 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
US20100130580A1 (en) * 2006-01-25 2010-05-27 Aciex Therapeutics, Inc. Formulations and Methods for Treating Dry Eye
US20090010850A1 (en) * 2007-05-24 2009-01-08 Ousler Iii George W Formulations and methods for treating dry eye
US20070254841A1 (en) * 2006-01-25 2007-11-01 Ophthalmic Research Associates, Inc. Formulations and methods for treating dry eye
CN101668511A (en) * 2007-02-28 2010-03-10 阿西克斯医疗公司 methods and compositions for normalizing meibomian gland secretions
CN101313899B (en) * 2007-06-01 2012-02-29 北京德众万全药物技术开发有限公司 Medicament composition for eyes containing sodium bromfenac
CN101965183A (en) * 2008-02-21 2011-02-02 伊斯塔药品公司 Eye NSAID as adjuvant
AU2009225931B9 (en) * 2008-03-17 2014-04-03 Novartis Ag Aqueous pharmaceutical compositions containing borate-polyol complexes
US8778999B2 (en) * 2009-03-05 2014-07-15 Insite Vision Incorporated Non-steroidal anti-inflammatory ophthalmic compositions
TWI489997B (en) * 2009-06-19 2015-07-01 Alcon Res Ltd Aqueous pharmaceutical compositions containing borate-polyol complexes
US8299295B2 (en) 2009-10-15 2012-10-30 Johnson Matthey Public Limited Company Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
GB2484843A (en) * 2009-10-15 2012-04-25 Johnson Matthey Plc Polymorphs of Bromfenac sodium
GB0919757D0 (en) * 2009-11-12 2009-12-30 Johnson Matthey Plc Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
RU2012124216A (en) * 2009-11-11 2013-12-20 Микро Лабс Лимитед PHARMACEUTICAL COMBINATION OF PROSTAGLANDINE AND NSAID COMPOUNDS FOR TREATMENT OF GLAUCOMA AND EYE HYPERTENSION
KR102075173B1 (en) * 2011-01-18 2020-02-07 센주 세이야꾸 가부시키가이샤 Bromfenac aqueous liquid composition having preservative efficiency
JP6012231B2 (en) * 2011-04-08 2016-10-25 ロート製薬株式会社 Bromfenac-containing composition
EP2701680B1 (en) 2011-04-29 2018-10-31 Allergan, Inc. Sustained release latanoprost implant
US20130023575A1 (en) * 2011-07-22 2013-01-24 Kamran Hosseini Compositions and methods for the treatment of ocular surface allergies
HUE069597T2 (en) 2011-10-12 2025-03-28 Bausch & Lomb Ocular composition containing bromfenac with increased bioavailability
US20130165419A1 (en) * 2011-12-21 2013-06-27 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
US20130217657A1 (en) * 2011-12-21 2013-08-22 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
JP6353365B2 (en) * 2012-09-27 2018-07-04 千寿製薬株式会社 Aqueous liquid
JP6161500B2 (en) * 2012-10-05 2017-07-12 ロート製薬株式会社 Bromfenac-containing composition
ES2664053T3 (en) * 2012-11-19 2018-04-18 Bausch & Lomb Incorporated Aqueous liquid composition containing 2-amino-3- (4-bromobenzoyl) phenyl-lactic acid
WO2014120293A1 (en) * 2013-01-31 2014-08-07 Sentiss Pharma Pvt.Ltd. Ophthalmic formulations
EP2952189B1 (en) 2013-01-31 2019-09-18 Senju Pharmaceutical Co., Ltd. Clear aqueous solution
CN105007918B (en) * 2013-01-31 2018-06-15 千寿制药株式会社 Stable aqueous liquid preparation
EP3010485A1 (en) 2013-06-19 2016-04-27 Sentiss Research Center Stable bromfenac solution
JP2015086222A (en) * 2013-09-26 2015-05-07 参天製薬株式会社 Stabilized 2-amino-3-(4-bromobenzoyl)phenylacetate-containing aqueous composition
WO2015087267A2 (en) 2013-12-12 2015-06-18 Sentiss Pharma Private Limited Stable bromfenac ophthalmic solution
CN104151182B (en) * 2014-06-16 2016-03-30 广东众生药业股份有限公司 The preparation method of a kind of Bromfenac sodium times semihydrate
US11452732B2 (en) 2015-09-05 2022-09-27 Randal Davis Homogeneous ophthalmic composition
US10130639B1 (en) 2015-09-05 2018-11-20 Randal Davis Homogeneous ophthalmic composition
CN106404952B (en) * 2016-08-31 2019-06-11 辰欣佛都药业（汶上）有限公司 A kind of measuring method of the sodium bromophenolate eye drops in relation to substance

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2880138A (en) 1956-12-24 1959-03-31 Upjohn Co Anti-inflammatory steroid solutions
US2880130A (en) 1956-12-24 1959-03-31 Upjohn Co Anti-inflammatory steroid solutions
CH577461A5 (en) * 1975-08-13 1976-07-15 Robins Co Inc A H
US4683242A (en) * 1985-10-28 1987-07-28 A. H. Robins Company, Incorporated Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters
GB8630273D0 (en) 1986-12-18 1987-01-28 Til Medical Ltd Pharmaceutical delivery systems
US5414011A (en) 1987-09-11 1995-05-09 Syntex (U.S.A.) Inc. Preservative system for ophthalmic formulations
FI94924C (en) 1987-09-11 1995-11-27 Syntex Inc Process for the preparation of an antimicrobial acting preservative system for ophthalmologically acceptable drugs
US5110493A (en) * 1987-09-11 1992-05-05 Syntex (U.S.A.) Inc. Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant
US4910225A (en) * 1988-01-27 1990-03-20 Senju Pharmaceutical Co., Ltd. Locally administrable therapeutic composition for inflammatory disease
JPH0283323A (en) * 1988-09-20 1990-03-23 Zeria Pharmaceut Co Ltd Stable riboflavin butyrate aqueous solution
JPH02124819A (en) 1988-11-01 1990-05-14 Mitsubishi Kasei Corp oral cholesterol lowering agents
JPH05223052A (en) 1992-02-06 1993-08-31 Kanematsu Eng Kk Current generator utilizing wave energy and hydrogen gas generator therewith
SG49746A1 (en) 1992-08-28 1998-06-15 Pharmos Corp Submicron emulsions as ocular drug delivery vehicles
AU6021794A (en) 1993-01-11 1994-08-15 Allergan, Inc. Ophthalmic compositions comprising benzyllauryldimethylammonium chloride
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
CN1091597C (en) 1994-03-15 2002-10-02 千寿制药株式会社 Method for stabilizing pranoprofen and stable liquid formulation of pranoprofen
ES2079320B1 (en) * 1994-05-17 1996-10-16 Cusi Lab OPHTHALMIC DISSOLUTION BASED ON A DICLOFENACO AND TOBRAMYCIN AND ITS APPLICATIONS.
US5475034A (en) * 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
AU3609795A (en) 1994-10-10 1996-05-02 Novartis Ag Ophthalmic and aural compositions containing diclofenac potassium
US5603929A (en) * 1994-11-16 1997-02-18 Alcon Laboratories, Inc. Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
US5558876A (en) * 1995-03-29 1996-09-24 Alcon Laboratories, Inc. Topical ophthalmic acidic drug formulations
US5750564A (en) * 1995-09-12 1998-05-12 Hellberg; Mark Anti-oxidant esters of non-steroidal anti-inflammatory agents
US6071904A (en) * 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
US6274592B1 (en) * 1997-02-04 2001-08-14 Senju Pharmaceutical Co., Ltd. Method for stabilizing arylcarboxylic acid, stabilizer thereof and aqueous solution containing stabilized arylcarboxylic acid
US5942508A (en) * 1997-02-04 1999-08-24 Senju Pharmaceutical Co., Ltd. Method for solubilizing pyridonecarboxylic acid solubilizer thereof and aqueous solution containing solubilized pyridonecarboxylic acid
TW546151B (en) 1997-07-23 2003-08-11 Senju Pharma Co Aqueous liquid pharmaceutical composition containing as main component benzopyran derivative
JPH11228404A (en) 1997-12-11 1999-08-24 Senju Pharmaceut Co Ltd Stable aqueous eye drop
US6066671A (en) * 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
US6162393A (en) * 1998-08-06 2000-12-19 Ndt, Inc. Contact lens and ophthalmic solutions
US6319513B1 (en) * 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
US6395746B1 (en) * 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US6369112B1 (en) * 1998-12-15 2002-04-09 Bausch & Lomb Incorporated Treatment of contact lenses with aqueous solution comprising a biguanide disinfectant stabilized by tyloxapol
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
AU6917400A (en) 1999-08-31 2001-03-26 Alcon Laboratories, Inc. Use of 5-ht1b/1d agonists to treat otic pain
CA2383971A1 (en) 1999-09-06 2001-03-15 Hiroaki Naka Prophylactic and therapeutic medicaments for ophthalmic diseases
AR030345A1 (en) 2000-08-14 2003-08-20 Alcon Inc METHOD OF TREATMENT OF DISORDERS RELATED TO ANGIOGENESIS
JP2002308764A (en) * 2001-02-09 2002-10-23 Taisho Pharmaceut Co Ltd Ophthalmic pharmaceutical composition
ATE393627T1 (en) * 2003-01-21 2008-05-15 Senju Pharma Co AQUEOUS LIQUID PREPARATION WITH 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID
JP4674162B2 (en) * 2003-11-14 2011-04-20 千寿製薬株式会社 Aqueous preparation containing aminoglycoside antibiotic and bromfenac
JP5223052B2 (en) 2010-05-21 2013-06-26 春誠 鈴木 Caulking gun
HUE069597T2 (en) * 2011-10-12 2025-03-28 Bausch & Lomb Ocular composition containing bromfenac with increased bioavailability
ES2664053T3 (en) * 2012-11-19 2018-04-18 Bausch & Lomb Incorporated Aqueous liquid composition containing 2-amino-3- (4-bromobenzoyl) phenyl-lactic acid

Also Published As

Publication number Publication date
ATE393627T1 (en) 2008-05-15
US20150025149A1 (en) 2015-01-22
ES2301964T3 (en) 2008-07-01
US8754131B2 (en) 2014-06-17
DE602004013420T2 (en) 2009-06-04
FR11C0031I2 (en) 2012-03-16
DE602004013420D1 (en) 2008-06-12
US9561277B2 (en) 2017-02-07
US20130090384A1 (en) 2013-04-11
CA3043910A1 (en) 2015-11-12
WO2015170177A1 (en) 2015-11-12
EP1586316B1 (en) 2008-04-30
US20050239895A1 (en) 2005-10-27
PT1586316E (en) 2008-05-28
US20070287749A1 (en) 2007-12-13
WO2004064828A1 (en) 2004-08-05
JP4500261B2 (en) 2010-07-14
CA2944832C (en) 2019-10-08
US20140235721A1 (en) 2014-08-21
US8497304B2 (en) 2013-07-30
DE122011100019I1 (en) 2011-11-03
US8871813B2 (en) 2014-10-28
US20140243413A1 (en) 2014-08-28
CN1700913A (en) 2005-11-23
CA2944832A1 (en) 2015-11-12
US8669290B2 (en) 2014-03-11
US8129431B2 (en) 2012-03-06
MX2016014404A (en) 2017-10-27
US20120115957A1 (en) 2012-05-10
US20150011634A1 (en) 2015-01-08
KR20050092691A (en) 2005-09-22
HK1083468A1 (en) 2006-07-07
US9144609B2 (en) 2015-09-29
US20140142183A1 (en) 2014-05-22
EP1586316A1 (en) 2005-10-19
HUS1100022I1 (en) 2017-04-28
US8927606B1 (en) 2015-01-06
KR101059711B1 (en) 2011-08-29
EP1586316A4 (en) 2007-06-27
JPWO2004064828A1 (en) 2006-05-18
CN100341498C (en) 2007-10-10

Similar Documents

Publication Publication Date Title
BE2011C027I2 (en)
RU2010139958A (en) STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING DOCETSAXEL
EP1689406A4 (en) HETEROCYCLIC MEK INHIBITORS AND METHODS OF USE THEREOF
NO20044406L (en) Stabilized liquid pharmaceutical composition as well as methods for increasing the stability of IL-2
ATE532797T1 (en) POLYMERIZABLE COMPOSITIONS CONTAINING SALTS OF BARBITURIC ACID DERIVATIVES
RS53418B (en) Pharmaceutical solutions, process of preparation and therapeutic uses
DK1605932T3 (en) Intranasal formulation of rotigotine
RU2011101713A (en) PHARMACEUTICAL COMPOSITION
JP2009178558A5 (en)
EA201490175A1 (en) COMPOSITIONS OF DEOXIC ACID AND ITS SALTS
CY1116189T1 (en) TREASURY-based STABLE LIQUID PHARMACEUTICAL COMPOSITION
MA30554B1 (en) POLYMORPHIC MALATES AND FORMS OF (3S, 5S) -7- [3-AMINO-5-METHYL-PIPERIDINYL] -1-CYCLOPROPYL-1,4-DIHYDRO-8-METHOXY-4-OXO-3-QUINOLINE ACID CARBOXYLIC
IL174248A0 (en) Alkyl carboxylic acid derivatives and pharmaceutical compositions containing the same
BR9908479A (en) Pharmaceutical compositions containing the phospholipase inhibitor [[3- (2-amino-1,2-dioxoethyl) -2-ethyl-1- (phenylmethyl_-1h-indol-4-yl] oxyl] sodium acetate
DK1459739T3 (en) Non-hydroscopic pharmaceutical compositions containing non-hydrated quinoline carboxylic acids
RU2007142498A (en) PHARMACEUTALLY ACTIVE DIAZEPANES
EA200801875A1 (en) ANTAGONIST CD 80
EA201490127A1 (en) OPHALMOLOGICAL SOLUTION CONTAINING HYALURONIC ACID OR ITS SALT AND PROPYLENE GLYCOL
RU2012117141A (en) COMPOSITIONS OF OLOPATADINE AND WAYS OF THEIR APPLICATION
MA30600B1 (en) AQUEOUS MEDICINAL FORMULATION OF 4 - [((4-CARBOXYBUTYL) - {2 - [(4-PHENETHYL-BENZYL) OXY] -PHENETHYL} AMINO) METHYL] BENZOIC ACID.
CN105530936A (en) Ophthalmic composition for zwitterionic soft contact lenses
WO2015087267A3 (en) Stable bromfenac ophthalmic solution
EP2284211A4 (en) AQUEOUS EMULSION CONTAINING A-OLEFIN / ACIDIC ACID ESTER COPOLYMER
JP4820648B2 (en) Loteprednol etabonate aqueous suspension
DE602006003848D1 (en) Formulation for the sustained release of valproic acid and its derivatives